
## Maria Teresa Fierro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7658291/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of Histologic Regression in Primary Melanoma With Sentinel Lymph Node Status. JAMA Dermatology, 2015, 151, 1301.	4.1	61
2	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 119, 168-178.	2.8	61
3	Mantle zone lymphoma: An immunohistologic study of skin lesions. Journal of the American Academy of Dermatology, 1994, 30, 23-30.	1.2	53
4	Metastatic melanoma of the heart. Journal of Surgical Oncology, 2000, 75, 203-207.	1.7	52
5	Blood Flow Cytometry in Sézary Syndrome. American Journal of Clinical Pathology, 2015, 143, 57-69.	0.7	45
6	Immature T lymphocytes in human cord blood identified by monoclonal antibodies: A model for the study of the differentiation pathway of T cells in humans. Cellular Immunology, 1984, 89, 194-201.	3.0	42
7	The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 736-739.	1.2	36
8	"Aleukemic" Granulomatous Leukemia Cutis. American Journal of Dermatopathology, 1998, 20, 417-421.	0.6	36
9	Expression Pattern of Chemokine Receptors and Chemokine Release in Inflammatory Erythroderma and Sézary Syndrome. Dermatology, 2006, 213, 284-292.	2.1	34
10	Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Research, 2007, 17, 75-82.	1.2	34
11	Primary cutaneous Bâ€cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. Cancer Medicine, 2016, 5, 2740-2755.	2.8	34
12	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody. Clinical Cancer Research, 2018, 24, 3377-3385.	7.0	31
13	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome. Journal of Investigative Dermatology, 2021, 141, 484-495.	0.7	31
14	Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. Journal of the American Academy of Dermatology, 2003, 49, 281-287.	1.2	28
15	Management of patients with atopic dermatitis undergoing systemic therapy during COVIDâ€19 pandemic in Italy: Data from the DAâ€COVIDâ€19 registry. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1813-1824.	5.7	28
16	Spiky follicular mycosis fungoides: a clinicopathologic study of 8 cases. Journal of Cutaneous Pathology, 2015, 42, 164-172.	1.3	27
17	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer, 2019, 121, 144-153.	2.8	27
18	Efficacy of dupilumab in prurigo nodularis in elderly patient. Dermatologic Therapy, 2020, 33, e13201.	1.7	25

Maria Teresa Fierro

#	Article	IF	CITATIONS
19	Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. Melanoma Research, 2004, 14, S17-S19.	1.2	24
20	Lymphokineâ€activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells. European Journal of Haematology, 1989, 42, 425-430.	2.2	23
21	Gauzeâ€based negative pressure wound therapy: a valid method to manage pyoderma gangrenosum. International Wound Journal, 2014, 11, 164-168.	2.9	23
22	Role of interferon in melanoma: old hopes and new perspectives. Expert Opinion on Biological Therapy, 2017, 17, 475-483.	3.1	21
23	Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 4561.	4.1	21
24	Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study. International Journal of Cancer, 2018, 142, 641-648.	5.1	20
25	THERAPEUTIC HOTLINE: A rare vandetanib-induced photo-allergic drug eruption. Dermatologic Therapy, 2010, 23, 553-555.	1.7	19
26	Long-Term Evolution of an Untreated Primary Cutaneous Follicle Center Lymphoma of the Scalp. American Journal of Dermatopathology, 2010, 32, 91-94.	0.6	18
27	TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk. Cancers, 2019, 11, 452.	3.7	17
28	Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study. Melanoma Research, 2004, 14, S9-S12.	1.2	16
29	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. Seminars in Oncology, 2020, 47, 302-304.	2.2	15
30	High-dose immunoglobulines and extracorporeal photochemotherapy in the treatment of febrile ulceronecrotic Mucha-Habermann disease. Dermatologic Therapy, 2010, 23, 419-422.	1.7	13
31	Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome. International Journal of Dermatology, 2015, 54, 1023-1029.	1.0	13
32	Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. Frontiers in Oncology, 2021, 11, 733770.	2.8	13
33	Chronic T-cell leukaemias. III. T-colonies, PHA response and correlation with membrane phenotype. Leukemia Research, 1982, 6, 809-814.	0.8	11
34	Expression and Role of Integrin Receptors in Sézary Syndrome. Journal of Investigative Dermatology, 1992, 99, 151-159.	0.7	11
35	Moderateâ€toâ€severe hidradenitis suppurativa under systemic therapy during the COVID â€19 outbreak. Dermatologic Therapy, 2020, 33, e13680.	1.7	11
36	Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience. Cancers, 2021, 13, 6071.	3.7	11

#	Article	IF	CITATIONS
37	Prevalence and significance of human parvovirus variants in skin from primary cutaneous T cell lymphomas, inflammatory dermatoses and healthy subjects. Archives of Dermatological Research, 2009, 301, 647-652.	1.9	10
38	Metastatic sebaceous cell carcinoma, review of the literature and use of electrochemotherapy as possible new treatment modality. Radiology and Oncology, 2016, 50, 308-312.	1.7	10
39	Flow cytometry immunophenotyping in mycosis fungoides. Journal of the American Academy of Dermatology, 2008, 59, 533-534.	1.2	9
40	TCRγ-Chain Gene Rearrangement by GeneScan: Incidence and Significance of Clonal Heterogeneity in Sézary Syndrome. Journal of Investigative Dermatology, 2010, 130, 2312-2319.	0.7	9
41	DNA from Human Polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in Cutaneous T-cell Lymphomas. Anticancer Research, 2018, 38, 4111-4114.	1.1	9
42	Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review. Oncotarget, 2021, 12, 1116-1121.	1.8	9
43	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. Journal of Clinical Medicine, 2021, 10, 5475.	2.4	8
44	Functional and phenotypical alterations of polymorphonuclear cells in Sézary syndrome patients. European Journal of Dermatology, 2011, 21, 921-929.	0.6	7
45	Functional and Phenotypical Impairment of Polymorphonuclear Cells in Atopic Dermatitis: An Additional Cause for the Known Susceptibility to Infections?. Dermatology, 2012, 224, 323-330.	2.1	7
46	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. Expert Opinion on Biological Therapy, 2015, 15, 1491-1500.	3.1	6
47	Identification of Risk Factors for Multiple Non-Melanoma Skin Cancers in Italian Kidney Transplant Recipients. Medicina (Lithuania), 2019, 55, 279.	2.0	6
48	Primary cutaneous B-cell lymphoma: narrative review of the literature. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 466-479.	0.8	6
49	Nutritional Interventions for Patients with Melanoma: From Prevention to Therapy—An Update. Nutrients, 2021, 13, 4018.	4.1	6
50	A meta-analysis of melanoma risk in industrial workers. Melanoma Research, 2020, 30, 286-296.	1.2	5
51	Case of bladder cancer during Dupilumab therapy: Just an incidental event?. Dermatologic Therapy, 2020, 33, e13854.	1.7	5
52	Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit. Future Oncology, 2021, 17, 759-761.	2.4	5
53	Lack of detection of Cutavirus DNA using PCR real time in cutaneous T-cell lymphomas. Giornale Italiano Di Dermatologia E Venereologia, 2021, 155, 772-774.	0.8	4
54	Treatment of metastatic melanoma: a multidisciplinary approach. Italian Journal of Dermatology and Venereology, 2017, 152, 241-261.	0.2	4

Maria Teresa Fierro

#	Article	IF	CITATIONS
55	The large spectrum of Spitzoid tumors: a retrospective survival study. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 315-320.	0.8	3
56	Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study. Dermatologic Therapy, 2022, 35, e15492.	1.7	3
57	Prognostic role of maspin expression in melanoma: probably far from clinical use. Histopathology, 2017, 71, 158-162.	2.9	2
58	Infections in Sézary syndrome: A retrospective cohort study of 113 patients. Journal of the American Academy of Dermatology, 2021, , .	1.2	2
59	Non-Sentinel Lymph Node Detection during Sentinel Lymph Node Biopsy in Not-Complete-Lymph-Node-Dissection Era: A New Technique for Better Staging and Treating Melanoma Patients. Journal of Clinical Medicine, 2021, 10, 4319.	2.4	2
60	Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient. European Journal of Dermatology, 2020, 30, 747-748.	0.6	2
61	CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study. Disease Markers, 2022, 2022, 1-7.	1.3	2
62	ALK expression favorably impacts the prognosis of NRAS‑mutated metastatic melanomas. Oncology Letters, 2018, 16, 7091-7096.	1.8	1
63	BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response. Future Oncology, 2019, 15, 133-139.	2.4	1
64	Immunological and Molecular Classification of Human Leukemias. , 1986, , 95-101.		1
65	COVID-19 infection and dermatologic surgery: management in a dermo-oncology center in a high-risk pandemic area. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 684-685.	0.8	1
66	Autoimmune connective tissue diseases and pregnancy. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 263-276.	0.8	1
67	A traveller's wart: tungiasis. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 236-237.	0.8	1
68	ls HERV-K and HERV-W expression regulated by mir-155 in Sézary Syndrome?. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 477-482.	0.8	1
69	Guttate psoriasis in a patient with mycosis fungoides in treatment with Brentuximab vedotin: An unreported association. Dermatologic Therapy, 2022, , e15309.	1.7	1
70	Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System. Cells, 2022, 11, 333.	4.1	1
71	Genetic mutations in primary malignant melanoma of the esophagus: case report and literature review. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 680-682.	0.8	1
72	Immunoglobulin DNA Analysis as a Marker of Clonality in the Follow-up of Patients with Hairy Cell Leukemia Treated with Alpha-Interferon. Leukemia and Lymphoma, 1990, 2, 103-110.	1.3	0

#	Article	IF	CITATIONS
73	CD27 mRNA expression in mycosis fungoides. Italian Journal of Dermatology and Venereology, 2021, , .	0.2	0
74	Prognostic role of histological regression in cutaneous melanoma. Italian Journal of Dermatology and Venereology, 2017, 152, 638-641.	0.2	0
75	Co-isolation and analysis of extracellular vesicle (EV)-associated DNA and cell free DNA (cfDNA) to improve the diagnostic and prognostic value of circulating BRAF V600E in metastatic melanoma patients Journal of Clinical Oncology, 2018, 36, e21564-e21564.	1.6	Ο
76	Tocilizumab and its usage for skin diseases. Italian Journal of Dermatology and Venereology, 2020, , .	0.2	0